Northwest Biotherapeutics

Bethesda, United States Founded: 1998 • Age: 28 yrs
Dendritic cell-based vaccines for prostate and brain cancers are developed.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a company based in Bethesda (United States) founded in 1998. It operates as a HealthTech. The company has 25 employees as of December 31, 2024. Northwest Biotherapeutics has completed 2 acquisitions, including Advent BioServices and Flaskworks. Northwest Biotherapeutics offers products and services including DCVax®-L, DCVax®-Direct, and DCVax®-Prostate. Northwest Biotherapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Bethesda, United States
  • Employees 25 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Northwest Biotherapeutics, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $1.38 M
    -28.47
    as on Dec 31, 2024
  • Net Profit
    $-83.78 M
    -33.83
    as on Dec 31, 2024
  • EBITDA
    $-64.46 M
    -19.88
    as on Dec 31, 2024
  • Latest Funding Round
    $5 M (USD), Post-IPO

    Dec 19, 2024

  • Investors
  • Employee Count
    25

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Northwest Biotherapeutics

Northwest Biotherapeutics is a publicly listed company on the OTC with ticker symbol NWBO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: OTC · Ticker: NWBO . Sector: Health technology · USA

Products & Services of Northwest Biotherapeutics

Northwest Biotherapeutics offers a comprehensive portfolio of products and services, including DCVax®-L, DCVax®-Direct, and DCVax®-Prostate. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Personalized vaccine developed for glioblastoma brain cancer treatment.

Vaccine designed for inoperable solid tumor cancer treatment.

Vaccine created for prostate cancer immunotherapy treatment solutions.

People of Northwest Biotherapeutics
Headcount 10-50
Employee Profiles 6
Employee Profiles
People
Les Goldman
SVP, Business Development
People
Linda F. Powers
CEO
People
Alton L. Boynton
Chief Scientific Officer
People
Marnix L. Bosch
Chief Technical Officer

Unlock access to complete

Funding Insights of Northwest Biotherapeutics

  • Total Funding
  • Total Rounds 23
  • Last Round Post-IPO — $5.0M
  • First Round

    (07 Jul 2010)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2024 Amount Post-IPO - Northwest Biotherapeutics Valuation

investors

Dec, 2021 Amount Post-IPO - Northwest Biotherapeutics Valuation

investors

Aug, 2020 Amount Post-IPO - Northwest Biotherapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Northwest Biotherapeutics

Northwest Biotherapeutics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Woodford Investment Management, Yorkville Advisors and Schulze Family Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Offers flexible capital to micro-cap and small-cap firms for growth.
Founded Year Domain Location
Diversified investment portfolios are managed for clients by the firm.
Founded Year Domain Location
Grants and scholarships are provided by this philanthropic foundation.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Northwest Biotherapeutics

Northwest Biotherapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Advent BioServices and Flaskworks. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Provides contract development, GMP manufacturing, and ultra-cold storage for cell therapy.
2016
Manufacturer of immunotherapeutics for research purpose
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Northwest Biotherapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Northwest Biotherapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Northwest Biotherapeutics

Northwest Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Northwest Biotherapeutics

Frequently Asked Questions about Northwest Biotherapeutics

When was Northwest Biotherapeutics founded?

Northwest Biotherapeutics was founded in 1998 and raised its 1st funding round 12 years after it was founded.

Where is Northwest Biotherapeutics located?

Northwest Biotherapeutics is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.

How many employees does Northwest Biotherapeutics have?

As of Dec 31, 2024, the latest employee count at Northwest Biotherapeutics is 25.

What is the annual revenue of Northwest Biotherapeutics?

Annual revenue of Northwest Biotherapeutics is $1.38M as on Dec 31, 2024.

What does Northwest Biotherapeutics do?

Northwest Biotherapeutics, Inc. is engaged in the development of personalized cancer vaccines aimed at treating a wide range of solid tumor cancers. The companys proprietary DCVax platform technology utilizes activated dendritic cells to create tailored immunotherapies. Products such as DCVax-L for glioblastoma, DCVax-Direct for inoperable tumors, and DCVax-Prostate for prostate cancer are developed through clinical trials. The focus is placed on advancing cancer treatment solutions within the healthcare and biotechnology sectors.

Who are the top competitors of Northwest Biotherapeutics?

Northwest Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

What products or services does Northwest Biotherapeutics offer?

Northwest Biotherapeutics offers DCVax®-L, DCVax®-Direct, and DCVax®-Prostate.

Is Northwest Biotherapeutics publicly traded?

Yes, Northwest Biotherapeutics is publicly traded on OTC under the ticker symbol NWBO.

How many acquisitions has Northwest Biotherapeutics made?

Northwest Biotherapeutics has made 2 acquisitions, including Advent BioServices, and Flaskworks.

Who are Northwest Biotherapeutics's investors?

Northwest Biotherapeutics has 3 investors. Key investors include Woodford Investment Management, Yorkville Advisors, and Schulze Family Foundation.

What is Northwest Biotherapeutics's ticker symbol?

The ticker symbol of Northwest Biotherapeutics is NWBO on OTC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available